NYU Langone study finds the hallucinogenic drug psilocybin, when combined with counseling, relieves depression and anxiety in cancer patients.
NYU Langone study shows that 2 doses of psilocybin combined with psychotherapy reduces alcohol consumption by 83 percent among heavy drinkers.
NYU Langone’s High School Bioethics Project examines PTSD and the ethical implications of using psychedelics like psilocybin to treat symptoms. Learn More
NYU Langone study finds a psychedelic drug improved emotional distress in people with cancer for nearly five years after treatment.
NYU Langone’s Dr. Michael P. Bogenschutz, Dr. Stephen Ross, and colleagues explore therapeutic agents such as psilocybin, cannabidiol, and MDMA.
NYU Langone psychiatrist Dr. Stephen Ross sees potential for psychedelic drugs to treat anxiety, depression, and other mental health disorders.
Three NYU Langone doctors discuss the impact of the COVID-19 pandemic on healthcare and new advances in their fields.
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from August 15, 2023.
Teachers may use our learning scenarios, or short bioethics primers, to supplement their curricula. Learn More
NYU Langone’s Department of Psychiatry conducts research to further understand substance use disorder causes and treatments. Learn More